Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and metallothionein

sorafenib has been researched along with metallothionein in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(metallothionein)		Trials
(metallothionein)		Recent Studies (post-2010) (metallothionein)
6,5207305,2519,390412,223

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, D; Chen, R; He, W; Kang, R; Niu, X; Sun, X; Tang, D1
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S1
Fu, X; Li, Z; Lin, R; Lu, Y; Wang, H; Wei, T; Zhang, J; Zhang, W1

Other Studies

3 other study(ies) available for sorafenib and metallothionein

ArticleYear
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Metallothionein; Mice, Nude; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Sorafenib

2016
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Molecular cancer, 2016, 05-16, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metallothionein; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Oxidative Stress; Phenylurea Compounds; Prognosis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Transcription, Genetic

2016
Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
    Pharmacological research, 2022, Volume: 180

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase IX; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Metallothionein; Signal Transduction; Sorafenib

2022